🇺🇸 FDA
Patent

US 9062347

Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy

granted A61KA61K31/404A61K31/4045

Quick answer

US patent 9062347 (Endothelin single nucleotide polymorphisms and methods of predicting β-adrenergic receptor targeting agent efficacy) held by The Regents of the University of Colorado, a Body Corporate expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/404, A61K31/4045, A61P, A61P9/00